Technogenetics Satellite Symposium
Together with our partner in Italy, Technogenetics, we are delighted to have two international experts in the field of molecular virology share their experience in clinical microbiology and laboratory management using our solutions (reagents and software) at the Technogenetics Satellite Symposium organized during the 20th ESCV annual meeting on Friday September 15th
2017 in Italy.
Advanced Biological Laboratories (ABL) S.A. and ABALAT S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Mexico.
We are pleased to share with you recent updates on ABL Diagnostics solutions:
Advanced Biological Laboratories (ABL) S.A. and SafeBlood BioAnalytica S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Greece.
ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for:
Advanced Biological Laboratories S.A. and Right to Care enter into an exclusive distribution and development collaboration (open source) agreement covering EQUIP in 17 developing countries to strengthen HIV (and other infectious disease) treatment and prevention.
Johannesburg (South Africa), Boston (USA), Luxembourg (Luxembourg Grand Duchy), Tuesday, 4 July 2017: Advanced Biological Laboratories (ABL) S.A. and Right to Care today announced that they entered into a license agreement for the distribution of ABL products. The agreement is open source access to ABL’s products for Right to Care and exclusive distribution rights in 17 countries covered by EQUIP, a USAID funded programme, led by Right to Care. The intention is to collaborate in the development, testing and scaling of innovative approaches that increase HIV testing, care and treatment. The implementation vehicle for this collaboration is a joint venture between the Right to Care Group and the Foundation for Professional Development Group called Qode.
The agreement is effective immediately and covers a large panel of ABL software (as well as all the future enhancements on such system following interactions with infectious diseases experts) including electronic medical record systems (TherapyEdge® and Nadis®), viral hepatitis web register (HepatiC®), Woman Health related web register (WHP), an innovative consolidation and reporting platform specifically designed for medical and related data (Octoplus™), and Sanger/NGS reagents and the related data analysis platform (ViroScore® and DeepChek®) software which are already CE & IVD certified.
“This is the first time in ABL history where we have provided access to the source code of our products to improve and adapt them to local needs. Through our relationship with Right to Care, we aim to provide broadest access at local pricing to contribute to improved patient clinical outcomes. Our large product portfolio consists of clinical and laboratory software, drug resistance and genotyping products in the field of infectious diseases (HIV, TB, Viral Hepatitis and other infections diseases). With the experience of Right to Care, we will build personalized tools, enable current and future programs led by PEPFAR and NGOs, to address specific needs to help the local populations and authorities benefit from optimal patient management systems and products,” said Dr Chalom Sayada, CEO of ABL.
Prof Ian Sanne, CEO of Right to Care, comments, “We are grateful for ABL’s vision to support developing countries with crucial data analysis requirements. We trust this collaboration will be mutually beneficial.”
ENDS
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ ,the DPM and Nadis® (thanks to the acquisition of Fédialis Médica in 2016) which are used for data and patient management, monitoring and personalized reporting applications. In 2012, TherapyEdge (respectively ViroScore® and DeepChek®-HIV ) received CE-marking (respectively CE-marking for IVD use). ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL’s DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
www.ablsa.com
About Right to Care
Right to Care is a South African non-profit organisation that supports and delivers prevention, care, and treatment services for HIV and TB. Through technical assistance, Right to Care supports the private sector, the Department of Health and the Department of Correctional Services. In addition, through direct service delivery, Right to Care treats patients for HIV, TB, cervical cancer and sexually transmitted infections. It leads the EQUIP consortium in 17 developing countries.
www.righttocare.org
About EQUIP
EQUIP supports the United States Agency for International Development’s (USAID) commitment, through the US President’s Emergency Plan for AIDS Relief (PEPFAR), to end the HIV/Aids epidemic, by fast-tracking cost effective treatment and prevention initiatives in 17 countries. With novel approaches, EQUIP supports the rapid diagnosis, viral suppression and linkage to sustained treatment for people living with HIV, ultimately working towards the UNAIDS 90-90-90 targets.
www.equiphealth.org
About Qode
Qode is a joint venture between Right to Care and the Foundation for Professional Development to house thirteen software offerings which are used in the development, testing and scaling of innovative approaches that reduce HIV/Aids. Qode will provide its products in 17 countries, through EQUIP, an initiative which works towards the eradication of HIV/Aids.
www.qode.healthcare
South Africa/Luxembourg, Tuesday, 4 July 2017: The Foundation for Professional Development (FPD) Group and Right to Care Group, joined forces to bring their healthcare technology under one umbrella for the advancement of health outcomes in developing countries. The new organisation which will house thirteen software offerings will be known as Qode and will service HIV/AIDS efforts in South Africa and seventeen developing countries through support of the EQUIP program.
Qode, through Right to Care Group, has further entered into a license agreement with Advanced Biological Laboratories (ABL) S.A. for the distribution, access and modification of ABL’s medical data and diagnostic software in the developing countries.
Using visual analytics, Qode enables healthcare organisations to explore clinical, financial and operational data which will lead to improvements in patient care, reduce costs and deliver higher value to patients. Gert van der Merwe, Executive Director of Qode says, “Qode’s strength lies in a deep understanding of the healthcare challenges of developing countries. This enables us to develop clinical systems that respond to data analysis requirements.”
Werner Swanepoel, Executive Director of Qode states that, “Qode is an African med-tech initiative which offers developing countries a level playing field in the fight against diseases like HIV/AIDS. Qode offers software solutions that provide insights into correlations in clinical data that we have not even begun to explore in many developing countries.”
Van der Merwe explains, “The FPD and Right to Care Groups’ clinical solutions were complementary, when paired with ABL’s offering – it made sense to combine efforts to offer comprehensive solutions to the developing healthcare industry.”
Says Dr Chalom Sayada, CEO of ABL, “This is the first time in ABL history where we have provided access to the source code of our products to improve and adapt them to local needs. We aim to provide the broadest access at local pricing thereby contributing to improved patient clinical outcomes.”
Qode will align to the Microsoft® Partner Network, as other FPD Group companies, under its commitment to the development, maintenance and support of sustainable software solutions.
ENDS
For more information please contact Turquoise PR & Marketing Communications:
About ABL
Advanced Biological Laboratories (ABL), S.A., is a medical data technology company founded in 2000. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems.
www.ablsa.com
About Right to Care Group
Right to Care Group is a South African non-profit organisation that supports and delivers prevention, care, and treatment services for HIV and TB. Through technical assistance, Right to Care supports the private sector, the Department of Health and the Department of Correctional Services. In addition, through direct service delivery, Right to Care treats patients for HIV, TB, cervical cancer and sexually transmitted infections. It leads the EQUIP consortium in 17 developing countries.
www.righttocare.org
About EQUIP
EQUIP supports the United States Agency for International Development’s (USAID) commitment, through the US President’s Emergency Plan for AIDS Relief (PEPFAR), to end the HIV/Aids epidemic, by fast-tracking cost effective treatment and prevention initiatives in 17 countries. With novel approaches, EQUIP supports the rapid diagnosis, viral suppression and linkage to sustained treatment for people living with HIV, ultimately working towards the UNAIDS 90-90-90 targets.
www.equiphealth.org
About FPD Group
The Foundation for Professional Development (FPD) was established in 1997 as a department in the South African Medical Association (SAMA). In 2000, FPD was registered as a separate legal entity and with the Department of Higher Education and Training (DHET) as a Private Higher Education Institution (PHEI) in terms of Section 54(1)(c) of the Act and Regulation 16(4)(a). FPD prides itself on being one of the few private higher educational institutions that fully engages in the three scholarships of higher education, namely: teaching and learning, research and community engagement.
www.foundation.co.za
About Qode
Qode is a joint venture between Right to Care and the Foundation for Professional Development to house thirteen software offerings which are used in the development, testing and scaling of innovative approaches that reduce HIV/Aids. Qode will provide its products in 17 countries, through EQUIP, an initiative which works towards the eradication of HIV/Aids.
www.qode.healthcare
Advanced Biological Laboratories (ABL) S.A. and Kron Científica e Industrial S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Guatemala.
Fédialis Médica a le plaisir de vous informer que les hôpitaux de la Pitié-Salpêtrière à Paris, ainsi que le CHU de Fort de France en Martinique utilisent notre logiciel CeGInaDis (version CeGIDD du logiciel NADIS) pour leurs activités de routine CeGIDD.
Advanced Biological Laboratories (ABL) S.A. and BADER SULTAN & BROTHERS CO W.L.L are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Kuwait.
Fédialis Médica a le plaisir de vous informer de la signature d’un partenariat avec l’AFRAVIH (www.afravih.org/) dans le but de tester l’utilisation du dossier médical informatisé NADIS pour le suivi et la prise en charge de patients vivant avec une pathologie chronique (VIH, hépatite, tuberculose, …) dans les Pays du Sud (en Afrique francophone essentiellement), en apportant aussi les modifications nécessaires à NADIS pour s’adapter aux besoins locaux (projet « Nadis SUD »).
Dans le cadre de ce partenariat et afin de faciliter la valorisation et l’implémentation de Nadis dans les établissements hospitaliers de ces pays, nous recrutons une personne
à temps plein qui aura des missions dédiées à la mise en œuvre de ce projet pour une première
période de douze mois (offre disponible ici)
ABL is pleased to announce the official release of its SeqHepB v6 interpretation system & database. Dedicated to the management of Viral Hepatitis B (HBV) sequencing data, the software can handle Capillary Electrophoresis or Next Generation Sequencing data, performs genotyping and mutation detection analyses of Polymerase, HBsAg, Core, Pre-core, Pre-S1, Pre-S2, X genes and is also compatible with Whole Genome analysis. It provides a comprehensive list of clinical interpretations including drug resistance, vaccine escape assessments or advanced liver disease prognosis.
ABL is pleased to announce the renewal and the extension of the Reseller rights given to ThermoFisher to promote ABL’s Capillary Electrophoresis sequencing data analysis software (ViroScore®), on a worldwide basis (except Spain). The platform is intended to be used for genotyping in Virology with a focus on multiple applications including : HIV, HBV, HCV, CMV, and soon HPV and other viruses.
